Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

Showing 1 to 11 of 11

TitleReference numberPublishedLast updated
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)TA1047
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinomaTA666
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA525
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520

Results per page

  1. 10
  2. 25
  3. 50
  4. All